Smith & Nephew plc - SNN STOCK NEWS

Smith+Nephew (LSE:SN, NYSE:SNN) announced FDA clearance for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems. These systems are now indicated for closed surgical incisions to reduce the risk of superficial and deep surgical site infections (SSIs), post-operative seromas, and dehiscence. Over 500,000 patients in the U.S. experience SSIs annually, leading to 8,000 deaths. The PICO system has been used in about 2.3 million surgical cases over the last decade, proving effective in managing post-surgical complications.

Smith+Nephew (NYSE: SNN) has acquired Engage Surgical, the owner of the only cementless unicompartmental knee system available in the US, for up to $135 million based on sales. This acquisition supports Smith+Nephew's growth strategy, enhancing its product portfolio with unique offerings in the knee implant market. The Engage Surgical Partial Knee System aims to improve patient outcomes through biologic integration and lower surgery times. The US partial knee market is projected to grow at 4% annually, presenting significant opportunities for Smith+Nephew.

Smith+Nephew (NYSE:SNN) has launched the CORI™ handheld robotics, an advanced solution for total and partial knee arthroplasties. This compact and mobile system integrates a 3-D imaging system with a robotic sculpting tool, allowing for personalized surgeries tailored to patient anatomy. Surgeons report improved patient outcomes, including less pain and greater satisfaction, as it enables tailored operations. The system aims to streamline surgical processes and is part of Smith+Nephew's five-year innovation strategy to enhance surgical experiences through digital technology.

Smith+Nephew (NYSE: SNN) has announced the establishment of a new digital surgery and robotics innovation center in Munich, Germany. This center aims to unite healthcare professionals from Europe, the Middle East, and Africa with Smith+Nephew's R&D teams to advance digital surgery technologies, including the CORI™ robotic system. The facility will feature a dedicated medical education area for hands-on learning and is scheduled to open in late 2022. This development follows the company's recent robotics facility in Pittsburgh, enhancing its collaborative approach to medical education and product development.

Smith+Nephew has established its first dedicated Medical Education Centre in Singapore to enhance the training of healthcare professionals in the Asia Pacific region. Set to begin operations by mid-2022, the centre will focus on digital and robotic surgery, integrating Smith+Nephew's Real Intelligence ecosystem. It will offer advanced training technologies including augmented reality and hands-on digital operating rooms. This initiative aligns with the company's mission to improve patient outcomes and support healthcare professionals' continuous education.

Smith+Nephew (NYSE:SNN) has launched the LEGION CONCELOC Cementless Total Knee System, showcasing its first completed surgeries. Utilizing CONCELOC Advanced Porous Titanium, this 3D printed technology promotes biological bone ingrowth for better long-term fixation. The system aims to streamline surgical efficiency, addressing challenges faced with traditional cementless designs. Now available in North America, it will expand into Europe and Asia Pacific pending regulatory approvals. This innovation positions Smith+Nephew in a growing market segment.

Smith+Nephew (NYSE:SNN) released a systematic review showing that its IODOSORB 0.9% Cadexomer Iodine Range is over twice as effective in healing chronic wounds compared to standard care. The analysis included 13 studies focusing on conditions like venous leg ulcers, diabetic foot ulcers, and pressure ulcers. IODOSORB significantly reduces barriers to healing such as exudate and bacteria. The cost of chronic wounds is estimated at $3.9 billion in Canada, highlighting the importance of effective treatments like IODOSORB in improving patient outcomes and reducing healthcare costs.

Smith+Nephew (NYSE:SNN) announced on Sept. 1, 2021, the launch of two innovations in its total knee arthroplasty (TKA) offerings: the JOURNEY II Medial Dished (MD) and SYNC Performance Instruments. These developments aim to enhance knee function and patient recovery. The JOURNEY II MD focuses on achieving natural knee kinematics, improving patient satisfaction with over 250,000 implementations reported. SYNC Performance Instruments streamline surgical procedures, reducing the number of instruments needed and enhancing ergonomics for surgeons, targeting a commercial release fall 2021.

Smith+Nephew (NYSE:SNN) announced enhancements to its Real Intelligence digital ecosystem and CORI Surgical System at the AAOS 2021 Annual Meeting. The highlights include the upcoming RI.HIP NAVIGATION software, pending FDA clearance, enabling robotic-assisted hip surgeries. Studies show that computer-guided technology significantly reduces revision rates (1.06% vs. 3.88%) and increases patient satisfaction. Furthermore, RI.INSIGHTS allows benchmarking for surgeons. The CORI System, noted for its portability and reduced costs, aims to innovate the orthopaedic space.